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Abstract
Background: Skin cutaneous melanoma (SKCM) is the most lethal form of skin cancer and while incidence rates
are declining for most cancers, they have been steadily rising for SKCM. Serine protease inhibitor, kunitz-type, 1
(SPINT1) is a type II transmembrane serine protease inhibitor that has been shown to be involved in the
development of several types of cancer, such as squamous cell carcinoma and colorectal cancer.
Methods: We used the unique advantages of the zebrafish to model the impact of Spint1a deficiency in early
transformation, progression and metastatic invasion of SKCM together with in silico analysis of the occurrence and
relevance of SPINT1 genetic alterations of the SKCM TCGA cohort.
Results: We report here a high prevalence of SPINT1 genetic alterations in SKCM patients and their association with
altered tumor immune microenvironment and poor patient survival. The zebrafish model reveals that Spint1a
deficiency facilitates oncogenic transformation, regulates the tumor immune microenvironment crosstalk,
accelerates the onset of SKCM and promotes metastatic invasion. Notably, Spint1a deficiency is required at both
cell autonomous and non-autonomous levels to enhance invasiveness of SKCM.
Conclusions: These results reveal a novel therapeutic target for SKCM.
Keywords: SPINT1, Melanoma, Inflammation, Tumor stroma, Epithelial to mesenchymal transition, Metastasis,
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Background
Skin cutaneous melanoma (SKCM) originates from
melanocytes, neural-crest derived pigment-producing
cells located in the epidermis, where their major func-
tion is to protect keratinocytes from UV-induced DNA
damage [1]. The malignant transformation of melano-
cytes generates this fatal form of skin cancer with a
complex multigenic etiology that becomes extremely
difficult to treat once it has metastasized. SKCM is the
deadliest form of skin cancer (75% of deaths related to
skin cancer) and it is common in the Western world.
Indeed, its global incidence is 15–25 per 100,000 individ-
uals [2]. While incidence rates are declining for most
cancers, they have been steadily rising for SKCM world-
wide [3]. Early detection is fundamental, since localized,
early stage SKCM can be surgically excised with little
chance of recurrence with a 98.2% of patient survival rate
after 5-year survival as reported by The Surveillance,
Epidemiology, and End Results (SEER) [4]. Metastatic
SKCM, however, is still an often fatal disease with a 5-year
survival rate of 15–20% [3].
SKCM is one of the most recurrent types of cancer
and its genetic heterogeneity has led in recent years to
join forces to determine SKCM causes and develop
effective therapies. Transformation of melanocytes into
primary and then metastatic SKCM requires a complex
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interplay of exogenous and endogenous events [5]. More
than 50% of the tumors originate from normal skin rather
than from dysplastic nevi, suggesting that SKCM not only
appears to be due to the transformation of mature mela-
nocytes [6]. In this way, the identification of SKCM initiat-
ing cells is really important to devising methods for early
detection and eradication of SKCM [7, 8]. Moreover,
SKCM stem cell populations have been characterized and
associated with tumor progression, immunoevasion, drug
resistance and metastasis [9].
Inflammation can play a key role in cancer, from initi-
ation of the transformed phenotype to metastatic spread.
Nevertheless, inflammation and cancer have a profound
yet ambiguous relationship. Inflammation (especially
chronic inflammation) has protumorigenic effects, but
inflammatory cells also mediate an immune response
against the tumor and immunosuppression is known to
increase the risk for certain tumors [10]. Nowadays, skin
cancers are also attributed to chronically injured or non-
healing wounds and scars or ulcers that occur at sites of
previous burns, sinuses, trauma, osteomyelitis, prolonged
heat and chronic friction. The incidence of malignancy
in scar tissues is 0.1–2.5% and it is estimated that under-
lying infections and inflammatory responses are linked
to 15–20% of all deaths from cancer worldwide [11].
Furthermore, chronic inflammation contributes to about
20% of all human cancers [12].
Serine protease inhibitor, kunitz-type, 1 (SPINT1),
also known as hepatocyte growth factor activator in-
hibitor 1 (HAI1), is a type II transmembrane serine
protease inhibitor that plays a crucial role in the regula-
tion of the proteolytic activity of both suppression of
tumorigenicity 14 (ST14), also known as Matriptase-1
[13–15], and Hepatocyte growth factor activator (HGFA)
[16]. The functional linkage between ST14 and SPINT1
has important implications for the development of cancer.
ST14 activity, which is only partially opposed by endogen-
ous SPINT1, causes increased sensitivity to carcinogens
and produces spontaneous tumorigenesis in the skin of
keratin-5-matriptase transgenic mice, while increased epi-
dermal SPINT1 expression fully counteracts the onco-
genic effect of ST14 [17]. Furthermore, the expression of
ST14 has been demonstrated to be up-regulated in various
human cancer histotypes such as breast, cervix, ovaries,
prostate, esophagus and liver cancers [18].
The close functional relationship between ST14 and
SPINT1 was also observed in a zebrafish model of skin in-
flammation, carrying a hypomorphic mutation of spint1a.
Indeed epidermal hyperproliferation and neutrophil infiltra-
tion observed in mutant zebrafish larvae are both rescued
by st14a gene knock-down, suggesting a novel role for the
SPINT1-ST14 axis in regulating inflammation [19, 20].
Given the unique advantages of the zebrafish model for
tumor cell transplantation, thanks to the transparency of
embryos and even adults that allows the tracking of donor
cells and the strong correlation between alterations of
Spint1a-St14a levels with tumor progression, the spint1a
mutant zebrafish represents an attractive model to study
the role of SPINT1 and chronic inflammation in SKCM.
Our results show that genetic alterations of SPINT1 cor-
related with a poor prognosis of SKCM patients and pro-
vide evidence that SPINT1 expression positively
correlated with tumor macrophage infiltration, but not
neutrophils. In line with these clinical data, we show that
Spint1a deficiency enhances at both cell autonomous and
non-autonomous levels cell dissemination of SKCM in
zebrafish models by promoting tumor dedifferentiation
and altered immune surveillance.
Methods
Animals
Wild-type zebrafish (Danio rerio H. Cypriniformes,
Cyprinidae) were obtained from the Zebrafish Inter-
national Resource Center (ZIRC, Oregon, USA) and
mated, staged, raised and processed as described in the
zebrafish handbook [21]. Zebrafish fertilized eggs were
obtained from natural spawning of wild type and transgenic
fish held at our facilities following standard husbandry
practices. Animals were maintained in a 12 h light/dark
cycle at 28 °C. Tg(kita:GalTA4,UAS:mCherry)hzm1 zebrafish
were crossed with Tg(UAS:eGFP-H-RAS_G12V)io6 line [8]
to express oncogenic human HRAS_G12V driven by the
melanocyte cell-specific promoter kita. Transgene expres-
sion was confirmed in 3 day post-fertilization larvae (dpf)
by fluorescence microscopy and by analyzing melanocyte
hyperproliferation [8]. The hi2217 line, which carries a
hypomorphic spint1a mutant allele that promotes skin
inflammation [19], and transparent roya9/a9; nacrew2/w2
(casper) [22] of 4–8month old were previously described.
Zebrafish larvae were anesthetized by a solution of
0.16 mg/ml buffered tricaine (Sigma-Aldrich) in embryo
medium. Adult zebrafish were anesthetized by a dual
anesthetic protocol to minimize over-exposure to tri-
caine, in long-term studies (up to 40 min) [23]. Briefly,
the anesthesia was firstly induced by tricaine and then
fish were transferred to tricaine/isoflurane solution
(forane in ethanol, 1:9).
Tumor sampling, disaggregation and cell sorting
Primary melanoma tumors were excised from adult
zebrafish once they had reached between 3 and 5mm in
diameter. Some individuals were euthanized according the
European Union Council and IUAC protocol and others
were monitored and maintained still alive after the tumor
biopsy treated with conditioners to reduce fish stress and
heal damaged tissue and wounds (STRESS COAT, API), as
well as to protect from bacterial (MELAFIX, API) and fun-
gal infections (PIMAFIX, API).
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The tumor was excised with a clean scalpel and razor
blade, placed in 2 ml of dissection media, composed by
DMEM/F12 (Life Technologies), 100 UI/ml penicillin,
100 μg/ml streptomycin, 0.075 mg/ml Liberase (Roche).
After manually disaggregation with a clean razor blade
and incubation at room temperature for 30 min, 5 ml of
wash media, composed by DMEM/F12 (Life Technolo-
gies), penicillin-streptomycin (Life Technologies), and
15% heat-inactivated FBS (Life Technologies), were
added to the tumor slurry and manually disaggregated
one last time. Next, the tumor cell suspensions were
passed through a 40 μm filter (BD) into a clean 50ml
tube. An additional 5 ml of wash media was added to the
initial tumor slurry and additionally filtered. This pro-
cedure was repeated twice. Cells were counted with a
hemocytometer and the tubes of resuspended cells were
centrifuged at 800 g for 5 min at 4 °C. The pellets of
tumor cells were resuspended in PBS containing 5% FBS
and kept on ice prior to transplantation [23].
The resulting cell suspension from zebrafish melan-
oma tumors was passed through a 40 μm cell strainer
and propidium iodide (PI) was used as a vital dye to
exclude dead cells. The Cell Sorting was performed on a
“Cell Sorter” SONY SH800Z in which eGFP positive
cells were sorted from the negative ones of the same cell
tumor suspension.
Larval allotransplantion assays
Melanomas were disaggregated, then labelled with 1,1′-
di-octa-decyl-3,3,3′,3′-tetra-methyl-indo-carbo-cya-nine
perchlorate (DiI, ThermoFisher) and finally resuspended
in a buffer containing 5% FBS in PBS. Between 25 to 50
cells/embryo were then injected in the yolk sac of 60–90
Casper or spint1 mutants zebrafish larvae of 48 h post-
fertilization (hpf) and after 5 days at 28 °C, larvae were
scored manually in blind samples for zebrafish melan-
oma cells dissemination by fluorescence microscopy
[24]. Melanoma cell invasion score was calculated as the
percentage of zebrafish melanoma cell-invaded larvae
over the total number of larvae analyzed taking into
account also the number of tumor foci per larvae. Three
tumor foci were established to score a larva as positive
for invasion. Furthermore, larvae positive for invasion
were also distinguished in three groups considering the
number of positive foci per larvae: 3–5 foci per larvae,
5–15 foci per larvae and > 15 foci per larvae.
Adult allotransplantion assays
Adult zebrafish used as transplant recipients were im-
munosuppressed to prevent rejection of the donor mater-
ial. Thus, the recipients were anesthetized, using the dual
anesthetic protocol described above, and treated with 30
Gy of split dose sub-lethal X-irradiation (YXLON SMART
200E, 200 kV, 4.5 mA) 2 days before the transplantation.
Then the immunosuppressed fish were maintained in
fresh fish water treated with conditioners preventing
infections onset and the consequent recipient deaths.
Anesthetized fish (10–20 per tumor) were placed
dorsal side up on a damp sponge and stabilized with one
hand. Using the other hand, the needle of a 10 μl bev-
eled, 26S-guaged syringe (Hamilton) was positioned
midline and ahead to the dorsal fin. 30,000, 100,000,
300,000 and 500,000 cells resuspended in PBS were
injected into the dorsal subcutaneous cavity. The syringe
was washed in 70% ethanol and rinsed with PBS between
uses. Following transplantation, fish were placed into a
recovery tank of fresh fish water and kept off-flow with
daily water changes for 7 days. Large and pigmented tu-
mors engrafted and were observed to expand by 10 days
post-transplantation.
SKCM imaging in adult zebrafish
Adult zebrafish were scored weekly for melanoma forma-
tion starting at the first appearance of raised lesions. Tumor
scoring was blinded and experiments were independently
repeated at least 3 times. Zebrafish were anesthetized,
placed in a dish of fish water and photographed using a
mounted camera (Nikon D3100 with a Nikon AF-S Micro
Lens). The pigmented tumor size was represented as the
number of pigmented pixels (Adobe Photoshop CS5).
Analysis of gene expression
Once zebrafish tumors reached between 3 and 5mm of
diameter, they were excised and total RNA was extracted
with TRIzol reagent (Invitrogen), following the manufac-
turer’s instructions, and then treated with DNase I, amp-
lification grade (1 U/μg RNA; Invitrogen). SuperScript
III RNase H− Reverse Transcriptase (Invitrogen) was
used to synthesize first-strand cDNA with oligo (dT)18
primer from 1 μg of total RNA at 50 °C for 50 min. Real-
time PCR was performed with an ABI PRISM 7500
instrument (Applied Biosystems) using SYBR Green
PCR Core Reagents (Applied Biosystems). Reaction mix-
tures were incubated for 10 min at 95 °C, followed by 40
cycles of 15 s at 95 °C, 1 min at 60 °C, and finally 15 s at
95 °C, 1 min 60 °C and 15 s at 95 °C. For each mRNA,
gene expression was normalized to the ribosomal pro-
tein S11 gene (rps11) content in each sample Pfaffl
method [25]. The primers used are shown in Add-
itional file 1: Table S1. In all cases, each PCR was per-
formed with triplicate samples and repeated at least in
two independent samples.
Human SKCM dataset analysis
Normalized gene expression, patient survival data, gen-
etic alterations and neutrophil/macrophage infiltration
were downloaded on 14th December 2017 from SKCM
repository of The Cancer Genome Atlas (TCGA,
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Provisional) from cBioPortal database (https://www.cbio
portal.org/). This cohort includes 479 patient samples.
No cleaning filter was applied and all patient data avail-
able for each study were used: 469 samples for expres-
sion analysis, 461 samples for survival analysis and 468
for immune cell infiltration. Transcript levels of SPINT1
in human samples from normal skin, benign and malig-
nant melanoma was collected from Gene Expression
Omnibus (GDS1375 dataset and 202826_at probe). Gene
expression plots and regression curves for correlation stud-
ies were obtained using GraphPad Prism 5.03 (GraphPad
Software).
Statistical analysis
Data are shown as mean ± SEM and they were analyzed by
analysis of variance (ANOVA) and a Tukey multiple range
test to determine differences between groups. The survival
curves were analysed using the log-rank (Mantel-Cox) test.
All the experiments were performed at least three times,
unless otherwise indicated. The sample size for each treat-
ment is indicated in the graph and/or in the figure legend.
Statistical significance was defined as p < 0.05.
Results
SPINT1 genetic alterations are associated with poor
prognosis of SKCM patients and altered tumor immune
microenvironment
To study the impact of SPINT1 in promoting SKCM
progression and aggressiveness, an in silico analysis of
human SKCM samples of the TCGA cohort was per-
formed. This analysis revealed that genetic alterations
occurred in 10% of SKCM patients; a relevant percent-
age comparing with major SKCM driven oncogenes and
tumor suppressors (Fig. 1a). Among these genetic alter-
ations, an increased mRNA level was the most prevalent
alteration (7%), while 1.9% missense mutations of un-
known significance and 1.9% deep deletions were also
observed. Notably, these genetic alterations of SPINT1
significantly correlated with poor SKCM patient progno-
sis (Fig. 1b) and SPINT1 expression was significantly
inhibited in human SKCM comparing with nevus and
normal skin (Fig. 1c). In addition, the analysis of patient
survival with increased SPINT1 transcript levels also
revealed their poor prognosis but, unfortunately, the
analysis of deep deletions and missense mutations separ-
ately gave no statistical significance because the number
of patients for each condition was very low (data not
shown). We next performed a GO enrichment analysis
of biological process (Fig. 1d), analyzing the differentially
expressed genes in SKCM samples of the TCGA cohort
with missense mutations or copy-number alterations of
SPINT1. The results showed that regulation of immune
system, inflammatory response, cell cycle, cell adhesion,
and extracellular matrix organization represent key
pathways significantly affected in human SKCM with
these SPINT1 genetic alterations. Collectively, these re-
sults suggest that both high and low levels of SPINT1 result
in an unbalanced crosstalk between tumor cells and their
microenvironment promoting higher aggressiveness.
The tumor microenvironment contains diverse leukocyte
populations, including neutrophils, eosinophils, dendritic
cells, macrophages, mast cells and lymphocytes [26]. It is
known that tumor-associated macrophages (TAM) are able
to interact with tumor cells and can promote cancer pro-
gression [27–29]. As shown in Fig. 1e, the number of TAM
in human SKCM samples correlated with the mRNA levels
of SPINT1 in metastatic SKCM. However, the number of
tumor-associated neutrophils (TAN) was independent of
SPINT1 levels in both primary and metastatic SKCM.
These data further confirmed the role of SPINT1 in the
regulation of the crosstalk between tumor and inflamma-
tory cells in human SKCM.
The expression of SPINT1 positively correlates with both
inflammation and macrophage markers in human SKCM
biopsies
In order to further understand the role of SPINT1 in
SKCM, the RNA Seq database of the large TCGA cohort of
SKCM was analyzed in terms of the expression of SOX10,
TYR and DCT genes, that have been shown to be important
in melanocyte development [30, 31]. In addition, SOX10 is
a recognized biomarker for the diagnosis of SKCM [30]. It
was found that SPINT1 expression positively correlated
with those of SOX10 and TYR, while a negative correlation
was found between the expression of SPINT1 and DCT
(Fig. 2a). The expression of the epithelial to mesenchymal
transition (EMT) markers ZEB1, ZEB2 and TWIST1, but
not TWIST2, negatively correlated with that of SPINT1 in
SKCM (Fig. 2b).
SKCM cells release several cytokines and chemokines
that recruit and polarize macrophages [32]. Therefore,
several inflammation markers were analyzed and only
the expression of the genes encoding the receptor of the
pro-inflammatory cytokine TNFα (TNFR1) and the re-
ceptor of the pro-inflammatory chemokine interleukin 8
(CXCR2), positively correlated with SPINT1 levels (Fig. 2c).
Notably, the macrophage markerMFAP4 also positively cor-
related with SPINT1 expression (Fig. 2d). However, the M2
polarization marker CD163 (Fig. 2d) and several interferon-
stimulated genes (ISGs) (Fig. 2e) were all unaffected by
SPINT1 levels. Collectively, these results further suggest that
SPINT1 regulates SKCM differentiation and aggressiveness,
and macrophages infiltration.
Inflammation accelerates the onset of SKCM in zebrafish
Given the strong correlation between alterations of SPINT1
levels with the progression of SKCM and the crosstalk with
the tumor immune microenvironment, we crossed the
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zebrafish line kita:Gal4;HRAS-G12V, which expresses the hu-
man oncogene HRAS-G12V in melanocytes and spontan-
eously develops SKCM [8], with the zebrafish mutant line
spint1ahi2217Tg/hi2217Tg [19], which presents chronic skin in-
flammation (Fig. 3a). Firstly, we quantified by fluorescence
microscopy the number of early oncogenically transformed
goblet cells, which also expressed the kita promoter [33], in
spint1a-deficient larvae and their wild type siblings (Fig. 3b).
The results showed that spint1a deficiency resulted in
increased number of HRAS-G12V+ cells (Fig. 3c). To deter-
mine if the enhanced Spint1a deficiency-driven oncogenic
transformation was also able to promote SKCM aggressive-
ness, SKCM development in spint1ahi2217Tg/hi2217Tg fish were
compared with wild type (spint1a+/hi2217Tg) from the end of
metamorphosis stage (between 28 and 30 dpf) to 120 dpf
(adult stage) (Fig. 3d-f). The resulting Kaplan-Meier curve
showed a significant increased incidence of melanoma
in the Spint1a-deficient fish, which developed SKCM in
more than 50% of cases at 50–60 dpf compared with
their wild type siblings which reached only 30% at this
age (Fig. 3f). These data suggest that Spint1a deficiency
increases oncogenic transformation and accelerates
SKCM onset in vivo.
Spint1a deficiency is required at cell autonomous and
non-autonomous levels to enhance SKCM cell
dissemination in a zebrafish larval allotrasplantation
model
To assess the in vivo role of Spint1a deficiency in SKCM in-
vasiveness, SKCM tumors from spint1ahi2217Tg/hi2217Tg; kita:
Gal4;HRAS-G12V and spint1a+/hi2217Tg; kita:Gal4;HRAS-
G12V were disaggregated, after staining the cells were trans-
planted into the yolk sac of 2 dpf casper zebrafish larvae
(Fig. 4a). The results showed that Spint1a deficiency in
SKCM cells enhanced the dissemination of SKCM, assayed
as the percentage of invaded larvae and the number of foci
per larva, compared to control SKCM cells (Fig. 4b-d). We
next examined whether Spint1a deficiency in the stroma, i.e.
in a non-autonomous manner, also promoted SKCM aggres-
siveness. Spint1a wild type SKCMs were transplanted into
the yolk sac of Spint1a-deficient and their wild type siblings
larvae (Fig. 4e). Strikingly, it was found that Spint1a defi-
ciency in the tumor microenvironment also promoted a
significantly higher dissemination of SKCM compared to
control tumor microenvironments (Fig. 4f-h).
To further confirm a role of Spint1a in both SKCM
and tumor microenvironment cells, we next sorted
tumor (eGFP+) and stromal (eGFP−) cells from both
genotypes and then mixed in equal proportions (~ 90%
of tumor and ~ 10% of stromal cells) in the 4 possible
combinations (Fig. 5a), since it was found that all tu-
mors had ~ 90% of tumor and ~ 10% of stromal cells
(data not shown). Notably, both Spint1a-deficient tumor
and stromal cells were able to increase SKCM cell inva-
sion (Fig. 5b and c). Collectively, these results suggest that
Spint1a deficiency enhances SKCM invasion by both cell
autonomous and non-autonomous mechanisms.
Spint1a-deficient SKCM cells showed enhanced
aggressiveness in adult zebrafish allotransplantation
model
The results obtained in allotransplantation assay in lar-
vae prompted us to analyze the role of Spint1a in SKCM
aggressiveness and metastasis in adult casper zebrafish
to directly visualize tumor cell proliferation and dissem-
ination over time. spint1ahi2217Tg/hi2217Tg and spint1a+/-
hi2217Tg SKCMs were sampled, disaggregated and
subcutaneously injected (300,000 cells) in the dorsal
sinus of adult casper recipients previously irradiated with
30 Gy (Fig. 6a). Tumor engraftment was visible as early as
7 days post-transplantation in both genotypes. While 90%
engraftment was obtained with wild type SKCM cells,
Spint1a-deficient cells showed a significant enhancement of
tumor engraftment rate, around 95% (Fig. 6b). In addition,
adult zebrafish recipients transplanted with Spint1a-deficient
SKCMs developed tumors with a significant higher growth
rate than those injected with wild type SKCMs (Fig. 6c).
Notably, Spint1a-deficient SKCM cells were able to invade
the entire dorsal area, part of ventral cavity and the dorsal
fin (Fig. 6c).
We next performed additional transplant assays fol-
lowing the same work-flow but injecting an increased
number of cells (500,000 cells per recipient fish), that
ensured a 100% of engraftment was for both genotypes
(data not shown). From the first week of analysis,
Spint1a-deficient SKCM tumor size was significantly
(See figure on previous page.)
Fig. 1 SPINT1 genetic alterations are associated with poor prognosis of SKCM patients. a Percentage of genetic alterations in oncogenes, tumor
suppressor genes and SPINT1 in SKCM patients of the TCGA cohort (n = 479). b Survival curve of patients with genetic alteration (increased mRNA
level, missense mutations and deep deletions, red line) vs. wild type (blue line) SPINT1 of SKCM of the TCGA cohort. Kaplan–Meier Gehan-Breslow-
Wilcoxon and nonparametric Log-rank Test. Hazard ratio = 1.625; 95% CI of ratio = 1.099–3.033. c Genetic expression of SPINT1 in human samples
from normal skin, nevus and malignant melanoma from GEO data set GDS1375 and 202826_at probe (n = 70). ***p < 0.001 according to ANOVA
and Tukey’s Multiple Comparison Test. d Enrichment analysis of GO biological process. Representation of the most significant GO biological
process altered when SPINT1 is affected by missense mutations or copy-number alterations. Analysis Type: PANTHER Overrepresentation Test
(Released 05/12/2017), Test Type: FISHER. e Number of infiltrated macrophages and neutrophils in SKCM samples of the TCGA cohort (n = 468).
The number of infiltrated cells in SKCM samples with low (blue) or high (red) SPINT1 mRNA levels according to the median. The mean ± S.E.M. for
each group is shown. *p < 0.05; **p < 0.01 according to Student t Tests
Gómez-Abenza et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:405 Page 6 of 14
Fig. 2 (See legend on next page.)
Gómez-Abenza et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:405 Page 7 of 14
larger than their control counterparts (Fig. 6d). In addition,
the recipients injected with Spint1a-deficient SKCM cells
developed larger tumors spanning the entire dorsal area
and even exceed the notochord line and grew vertically, a
clear aggressiveness signature of SKCM (Fig. 6d).
To further investigate the aggressiveness potential of
Spint1a-deficient SKCMs, a serial dilution assay was per-
formed following the work-flow previously described in
Additional file 1: Figure S1. Cells from both Spint1a-de-
ficient and wild type SKCMs were serially diluted and 3
different numbers of cells (30,000 cells, 100,000 cells and
300,000 cells) were transplanted into recipients as de-
scribed above. Notably, while 30,000 and 100,000
Spint1a-deficient SKCM cells were able to engraft and
the tumor grew over the time, wild type SKCMs hardly
grew (Additional file 1: Figure S1A, S1B). However,
Fig. 3 Inflammation accelerates the onset of SKCM in zebrafish. a Schematic diagram of the generation of the SKCM model line in zebrafish with
Spint1a deficiency. b and c Representative images (b) and number of early oncogenically transformed eGFP-HRAS-G12V+ cells in the boxed area
(c) in Spint1a-deficient larvae and control siblings at 3 dpf. Note the morphological alterations observed in the inflamed skin of the mutants
(white arrows). eGFP-HRAS-G12V+ goblet cells are marked with white arrows. Scale bar 250 μm. Each point on the scatter plot represents one
larva and the mean ± SEM is also shown. ** p < 0.05 according to an unpaired Student t test with Welch’s correction. d-f Impact of Spint1a
deficiency on SKCM onset in zebrafish. Representative images of whole fish (d) and of nodular tail tumors (e), and Kaplan-Meier curve showing
the percentage of SKCM-free fish in control and Spint1a-deficient adult fish (f). p < 0.0001 according to a Log rank Mantel-Cox test; Hazard ratio =
0.7962; 95% CI of ratio = 0.6834–0.9056
(See figure on previous page.)
Fig. 2 SPINT1 expression correlates with aggressiveness marker expression in human SKCM biopsies. Correlation of SPINT1 gene expression with
those of the melanocyte differentiation markers SOX10, TYR and DCT (a) the EMT markers ZEB1, ZEB2, TWIST1 and TWIST2 (b), the inflammation
markers TNFA, TNFR1, TNFR2, IL8 (CXCL8), CXCR2, IL6 and IL6R (c), the macrophage markers MFAP4 and CD163 (d) and the interferon markers ISG15
and IFIT1 (e) in human SKCM biopsies of the TCGA cohort. The statistical significance of the correlation was determined using Pearson’s
correlation coefficient. A linear regression-fitting curve in red is also shown
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injection of 300,000 Spint1a-deficient SKCM cells re-
sulted in large tumor spanning the entire dorsal area
and invading part of the ventral cavity (Additional file 1:
Figure S1C), confirming previous results. Collectively, all
these results confirm that Spint1a deficiency enhances
SKCM aggressiveness.
Spint1a deficiency promotes SKCM dedifferentiation and
inflammation
To understand the mechanisms involved in the Spint1a-
mediated aggressiveness of SKCM, the expression of genes
encoding important biomarkers was analyzed by RT-
qPCR. The mRNA levels of sox10, tyr, dct and mitfa were
lower in Spint1a-deficient SKCMs than in their wild type
counterparts (Additional file 1: Figure S2). In addition,
while the transcript levels of mmp9 and slug were similar
in Spint1a-deficient and wild type SKCM, cdh1 levels sig-
nificantly decreased in Spint1a-deficient compared to wild
type SKCM (Additional file 1: Figure S2).
We next analyzed genes encoding key inflammatory
molecules and immune cell markers, including the pro-
inflammatory cytokine Il1b, the neutrophil markers Lyz
Fig. 5 Spint1a deficiency both in stromal and tumor cell enhances SKCM dissemination in zebrafish larval model. a Allotransplant experimental
design. Combinations of Spint1a-deficient tumor and stromal cells from SKCMs were mixed with wild type tumor and stromal cells. All possible
cell combinations were obtained maintaining the initial ratio. b Representative images (overlay of bright field and red channels) of the invasion in
wild type recipient larvae at 5 dpi. Bar: 500 μm. c Number of tumor foci per larva (n = 5 SKCM tumors). **p < 0.01 according to a Chi-square Test
(See figure on previous page.)
Fig. 4 Spint1a deficiency is required at cell autonomous and non-autonomous levels to enhance SKCM cell dissemination in a zebrafish larval
allotrasplantation model. Analysis of dissemination of control and Spint1a-deficient SKCM allotransplants in wild type larvae (a-d) and SKCM
allotransplants in wild type and Spint1a-deficient larvae (e-h). a and e Experimental design. b and f Representative images (overlay of bright field
and red channels) of SKCM invasion at 5 dpi. Bars: 500 μm. c and g Percentage of invaded larvae for both tumor genotypes. Each dot represents
a single tumor and the mean ± SEM is also shown. **p < 0.01, ***p < 0.0001 according to unpaired Student t test. d and h Number of tumor foci
per larva. ***p < 0.0001 according to Chi-square Tests
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Fig. 6 (See legend on next page.)
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and Mpx, the macrophage marker Mpeg1, and the ISGs
B2m, Mxb and Pkz, in Spint1a-deficient and wild type
SKCMs (Additional file 1: Figure S2). Curiously, it was
found that while il1b, lyz and mpx mRNA levels were
not affected by Spint1a deficiency, those of mpeg1 were
elevated in Spint1a-deficient SKCMs. Furthermore, the
ISGs b2m, mxb and pkz genes showed enhanced mRNA
levels in Spint1a-deficient SKCMs. These results point
out to altered immune surveillance and tumor cell dedif-
ferentiation promoted by Spint1a-deficiency in SKCM.
Discussion
The relationships between inflammation and cancer are
ambiguous. Although it is estimated that underlying infec-
tions and inflammatory responses are linked to 15–20% of
all deaths from cancer worldwide [11], immunosuppres-
sion is known to increase the risk for certain tumors [10].
Furthermore, immunotherapy is considered the most
promising cancer therapy for the next future [34]. In this
study, we have developed a preclinical zebrafish model to
study the role of SPINT1-driven skin chronic inflamma-
tion in melanoma. We found that Spint1a deficiency is
required at both cell autonomous and non-autonomous
levels to enhance cell dissemination of SKCM by promot-
ing tumor dedifferentiation and altered immune surveil-
lance. These results may have important clinical impact,
since genetic alterations of SPINT1 were found in 10% of
SKCM patients and correlated with altered cell cycle,
differentiation and innate and adaptive immune signaling
pathways and, more importantly, with a poor prognosis.
In addition, a positive correlation of both inflammation
and macrophage marker with SPINT1 levels was found in
tumor samples, fitting the increased number of TAM in
SKCM with high SPINT1 levels. However, a negative
correlation of SPINT1 and EMT marker levels was ob-
served, suggesting that SPINT1 levels critically regulate
tumor and immune cell crosstalk. Therefore, both high
and low levels of SPINT1 result in an unbalanced cross-
talk between tumor cells and their microenvironment pro-
moting higher SKCM aggressiveness.
Another interesting observation is that SPINT1 transcript
levels positively correlated with macrophage infiltration, but
not neutrophil one, in SKCM tumor samples. Similarly, our
gene expression studies also suggest that Spint1a regulates
macrophage infiltration in the zebrafish SKCM model.
Curiously, activated neutrophils in a condition of repeated
wounding have been shown to interact with pre-neoplastic
cells promoting their proliferation through the release of
prostaglandin E2 and, more importantly, SKCM ulceration
correlates with increased neutrophil infiltration and tumor
cell proliferation, which are both associated with poor prog-
nosis [35]. Although we found a robust positive correl-
ation between the transcript levels of SPINT1 and
CXCR2, which encodes a major IL-8 receptor involved
in SKCM neutrophil infiltration [36], CXCR2 has also
been shown to promote tumor-induced angiogenesis
and increased proliferation [37–39] and, therefore, the
SPINT1/CXCR2 axis may regulate SKCM aggressive-
ness by neutrophil-independent pathways.
The zebrafish model developed in this study uncov-
ered a role for Spint1a in facilitating oncogenic trans-
formation which probably accelerates the SKCM onset.
Curiously, Spint1a deficiency seems to have a prominent
role in oncogenic transformation accelerating SKCM
onset in vivo. However, the strong oncogenic activity of
HRAS-G12V, which is even able to induce melanoma
without the need of coadjuvating mutations in tumor
suppressors, results in a similar tumor burden in wild
type and Spint1a-deficient fish at later stages. It would
be interesting, therefore, to analyze in future studies the
impact of Spint1a in SKCM models driven by other
major oncogenes, such as Braf, Kras, Nras and Nf1.
Although SPINT1 is a serine protease inhibitor with
several targets, including ST14 and HGFA, deregulation
of the SPINT1/ST14 axis leads to spontaneous squa-
mous cell carcinoma in mice [17] and keratinocyte
hyperproliferation in zebrafish [19, 20] preceded by skin
inflammation in both models. In addition, intestine-spe-
cific Spint1 deletion in mice induces the activation of
the master inflammation transcription factor NF-κB and
accelerated intestinal tumor formation [40]. Strikingly,
pharmacological inhibition of NF-κB activation reduces
the formation of intestinal tumors in Spint1-deficient
ApcMin/+ mice [40], unequivocally demonstrating that
Spint1-driven inflammation promotes tumorigenesis.
The SKCM allotransplant assays in larvae revealed for
the first time that Spint1a deficiency in both tumor and
stromal cells increases SKCM invasiveness. In addition,
Spint1a deficiency in both cell types does not show
enhanced invasiveness compared to Spint1a deficiency
in either cell type. This is an interesting observation,
since SPINT1 is a membrane-bound protein that may,
therefore, inhibit their targets in both tumor cell autono-
mous and non-autonomous manners. However, wild
(See figure on previous page.)
Fig. 6 Spint1a-deficient SKCM shows enhanced aggressiveness in adult zebrafish allotransplantation assays. a Experimental workflow of adult
allotransplantation experiments in pre-irradiated adult casper zebrafish. b Percentage of engraftment for both control and Spint1a-deficient
tumors. Each dot represents a single SKCM tumor and the mean ± SEM is also shown (n = 5). c and d Representative images and average tumor
size (pixels) from 1 to 4 weeks post-transplant of primary (c) and secondary (d) transplants. Each dot corresponds to a recipient-transplanted fish
and the mean ± SEM is also shown. b-d *p < 0.05, **p < 0.01, ***p < 0.001 according to unpaired Student t test
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type Spint1a tumor microenvironment fails to compen-
sate its loss in tumor cells, since Spint1a-deficient tumor
cells show enhanced invasiveness in wild type larvae and
adult recipients, and vice versa. Importantly, transplant-
ation experiments of serial diluted SKCM cells revealed
the crucial cell-autonomous role of Spint1a in inhibiting
tumor aggressiveness. Similarly, loss of SPINT1 in hu-
man pancreatic cancer cells promotes ST14-dependent
metastasis in nude mouse orthotopic xenograft models
[41]. We observed that genetic alterations in SPINT1
transcript levels in SKCM patient samples negatively
correlated with EMT markers and that Spint1a-deficient
zebrafish SKCM showed reduced cdh1 mRNA levels.
EMT phenotype switching has been shown to be in-
volved in acquisition of metastatic properties in the
vertical growth phase of SKCM [42] and loss of E-cad-
herin, with gain of N-cadherin and osteonectin, was as-
sociated with SKCM metastasis [43]. Importantly, the
presence of aberrant E-cadherin expression in primary
and metastatic SKCM is associated with a poor overall
patient survival [44]. Therefore, our results suggest that
SPINT1 loss may facilitate metastatic invasion of human
SKCM through EMT phenotype switching.
Conclusions
We have developed a preclinical model to study the role
of altered expression of SPINT1 in early transformation,
progression and metastatic invasion in SKCM. This
model has revealed that Spint1a deficiency facilitates
oncogenic transformation, regulates the tumor/immune
microenvironment crosstalk and is associated to SKCM
aggressiveness. In addition, Spint1a deficiency in either
tumor or microenvironment compartment increases
SKCM aggressiveness. The high prevalence of SPINT1
genetic alterations in SKCM patients and their associ-
ation with a poor prognosis, point out to SPINT1 as a
novel therapeutic target for the treatment of SKCM.
Additional file
Additional file 1: Figure S1. Spint1a-deficient SKCM shows enhanced
aggressiveness in adult zebrafish allotransplantation assays. Control and
Spint1a deficient SKCMs were disaggregated and 30,000 (a), 100,000 (b)
and 300,000 cells (c) were injected subcutaneously in pre-irradiated adult
casper zebrafish. Fish were analyzed for average tumor size (pixels) from
1 to 4 weeks post-transplant. Representative images and quantification of
the average tumor size are shown. Each dot corresponds to a recipient-
transplanted fish and the mean ± SEM is also shown (n=2 SKCM
tumors).*p<0.05, ***p<0.001 according to unpaired Student t test. Figure
S2. Expression analysis of differentiation melanocyte, EMT, inflammation
and immune cell markers in zebrafish SKCM. The mRNA levels of the
genes encoding the differentiation melanocyte markers sox10, mitfa, tyr
and dct, the EMT markers cdh1, slug and mmp9, the inflammation marker
il1b, the neutrophil markers lyz and mpx, the macrophage marker mpeg1,
and the ISGs b2m, mxb and pkz were analyzed by RT-qPCR in control and
Spint1a-deficient SKCMs. *p < 0.05, **p<0.01 according to one-tailed
Student t test. Table S1. Primers used in this study for RT-qPCR. The
gene symbols followed the Zebrafish Nomenclature Guidelines (http://
zfin.org/zf_info/nomen.html/). ENA, European Nucleotide Archive (http://
www.ebi.ac.uk/ena/). (PDF 496 kb)
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